部分抗结核分枝杆菌药物的耐药机理研究进展

摘要/Abstract

摘要： 结核病是危害严重的重大传染病之一，抗结核药物的应用在治疗结核病的过程中具有重要意义。然而抗结核药物治疗不当会引起耐多药和广泛耐药结核分枝杆菌的出现，导致结核病抬头。结核的耐药多与耐药基因突变有关，笔者总结了常见抗结核药物的耐药分子机制的研究进展，为耐药结核的诊断和治疗提供分子依据。

关键词: 抗结核药, 抗生素类, 抗结核, 抗药性, 细菌

Abstract: Tuberculosis was one of most serious infectious diseases that were harmful to human health. Antibiotics was effective treatment against this bacterium. But the emergency of multi- and extensively drug-resistant Mycobacterium tuberculosis(Mtb) were occurred frequently when the use of antibiotics was unproper. Drugresistant phenotype was due to mutations in drug resistant related genes, this paper will state the progress in mechanism study of drug resistant Mtb, which will guide the diagnosis and treatment of drug resistant Mtb.

Key words: Antitubercular agents, Antibiotics, antitubercular, Drug resistance, bacterial

丁海榕秦川占玲俊. 部分抗结核分枝杆菌药物的耐药机理研究进展[J]. 中国防痨杂志, 2013, 35(8): 615-620.

DING Hai-rong, QIN Chuan, ZHAN Ling-jun. Advances in reseach on Mycobacterium tuberculosis drug resistance mechanism[J]. Chinese Journal of Antituberculosis, 2013, 35(8): 615-620.

参考文献

［1］全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告.中国防痨杂志，2012,34（8）：485-508.
［2］Wirth T, Hildebrand F, Allix-Béguec C, et al.Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog,2008,4(9):e1000160.
［3］Motiwala AS, Dai Y, Jones-López EC,et al. Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanisms.J Infect Dis,2010,201(6):881-888.
［4］Marttila HJ,Soini H,Eerola E,et al.A Ser315 Thr substitution in katG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St.Petersburg area in Russia.Antimicrob Agents Chemother,1998,42(9):2443-2445.
［5］Coll P, Aragón LM, Alcaide F,et al.Molecular analysis of isoniazid and rifampin resistance in Mycobacterium tuberculosis isolates recovered from Barcelona. Microb Drug Resist,2005,11（2）:107-114.
［6］Haas WH, Schilke K, Brand J, et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa.Antimicrob Agents Chemother，1997,41（7）:1601-1603.
［7］Musser JM, Kapur V, Williams DL, et al. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.J Infect Dis，1996,173（1）:196-202.
［8］Rouse DA,Morris SL. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis.Infect Immun,1995,63(4):1427-1433.
［9］Lee AS, Tang LL, Lim IH,et al.Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore.J Infect Dis，1997,176（4）:1125-1126.
［10］Cockerill FR 3rd, Uhl JR, Temesgen Z, et a1．Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase(KatG)gene associated with isoniazid resistance．J Infect Dis,1995，171(1)：240-245.
［11］Banerjee A, Dubnau E, Quemard A,et al.inhA,a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science，1994,263(5144):227-230.
［12］Dessen A, Quémard A, Blanchard JS, et al. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science,1995,267（5204）:163-1641.
［13］Rozwarski DA, Grant GA, Barton DH, et al.Modification of the NADH of the isoniazid target(inhA)from Mycobacterium tuberculosis. Science,1998,279（5347）:98-102.
［14］Zhang Y,Young D. Molecular genetics of drug resistance in Mycobacterium tuberculosis.J Antimicrob Chemother,1994,34(3):313-319.
［15］Morlock GP,Metchock B,Sikes D,et al.ethA,inhA,and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2003, 47(12): 3799-3805.
［16］Ano H,Matsumoto T,Nangi T,et al.Resistance-conferring mutations of Mycobacterium tuberculosis strains with low level resistance to isoniazid. Kekkaku,2006,81(12):709-713.
［17］Guo H,Seet Q,Denkin S,et al. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.J Med Microbiol, 2006,55(Pt 11):1527-1531.
［18］Larsen MH, Vilchèze C, Kremer L, et al.Overexpression of inhA,but not kasA,confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M.Bovis BCG and M.tuberculosis. Mol Microbiol,2002,46(2):453-466.
［19］Lee AS,Lim IH,Tang LL,et al.Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore.Antimicrob Agents Chemother,1999,43(8):2087-2089.
［20］Piatek AS,Telenti A,Murray MR,et al.Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons:implications for rapid susceptibility testing.Antimicrob Agents Chemother,2000,44(1):103-110.
［21］Lee AS, Teo AS, Wong SY.Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates.Antimicrob Agents Chemother,2001,45(7):2157-2159.
［22］Enne VI,Delsol AA,Roe JM,et al.Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother,2004,53(2):203-207.
［23］Lee JH,Ammerman NC,Nolan S,et al.Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis.Nat Commun,2012,3(753):1-8.
［24］Viader-Salvadó JM, Luna-Aguirre CM, Reyes-Ruiz JM,et al.Frequency of mutations in ropB and codons 315 and 463 of katG in rifampin- and/or isoniazid-resistant Mycobacterium tuberculosis isolates from northeast Mexico.Microb Drug Resist,2003,9(1):33-38.
［25］Mokrousov I,Narvskaya O,Otten T,et al.High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from morthwestern Russia,1996 to 2001.Antimicrob Agents Chemother, 2002, 46(5):1417-1424.
［26］熊札宽.结核病实验诊断学.北京：人民卫生出版社，2008：54-68.
［27］Moghazeh SL,Pan X,Arain T,et al.Comparative antimycobacterial activities of riampin,rifapentine,and KRM-1648 against a collection of rifamin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother,1996,40(11):2655-2657.
［28］Ohno H,Koga H,Kohno S,et al.Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother,1996,40(4):1053-1056.
［29］徐瑛.耐多药结核病研究进展.预防医学情报杂志,2008,24(4):290-292.
［30］Zhang Y,Mitchison D. The curious characteristics of pyrazinamide: a review.Int J Tuberc Lung Dis,2003,7(1):6-21.
［31］Unissa AN,Selvakumar N,Hassen S.Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. Bioinformation,2009,4(1):24-29.
［32］Petrella S,Gelus-Ziental N,Maudry A,et al.Crystal structrure of the pyrazinamidase of Mycobacterium tuberculosis:insights into natural and acquired resistance to pyrazinamide.PLoS One,2011,6(1）：1-8.
［33］洪创跃，刘小立，桂静，等.耐多药结核分枝杆菌pncA基因突变特征及与吡嗪酰胺耐药相关性研究.中华预防医学杂志,2012,46(5)：436-439.
［34］Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, et al. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.Infect Genet Evol,2013, pii: S1567-1348(12)00395-4.
［35］Shi W,Zhang X,Jiang X,et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.Science,2011,333(6049):1630-1632.
［36］Mokrousov I,Otten T,Vyshnevskiy B,et al. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing.J Clin Microbiol,2002,40(10):3810-3813.
［37］Ramaswamy SV, Amin AG, Gksel S, et al.Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis.Antimicrob Agents Chemother,2000,44(2):326-336.
［38］Dobner P, Bretzel G, Rüsch-Gerdes S, et al.Geographic variation of the predictive values of genomic mutations associated with streptomycin resistance in Mycobacterium tuberculosis.Mol Cell Probes,1997,11(2):123-126.
［39］Okamoto S, Tamaru A, Nakajima C, et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol,2007,63(4):1096-1106.
［40］Maus CE,Plikaytis BB,Shinnick TM.Molecular analysis of cross-resistance to capreomycin,kanamycin,amikacin,and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother,2005,49(8):3192-3197.
［41］Zaunbrecher MA,Sikes RD Jr,Metchock B,et al.Over expression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A,2009,106(47):20004-20009.
［42］刘雪梅，谢建平.卷曲霉素作用机制和耐药机制的功能基因组学研究进展.药学学报,2008,43(8):788-792.
［43］Giannoni F,Iona E,Sementilli F,et al.Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.Antimicrob Agents Chemother,2005,49(7):2928-2933.
［44］李国利，陈澎，孙昌文,等.结核分枝杆菌对左氧氟沙星与莫西沙星的交叉耐药性及gyrA和gyrB基因突变分析.中国防痨杂志,2010,32(10):616-621.
［45］Hegde SS, Vetting MW, Roderick SL, et al, A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science,2005,308(5727):1480-1483.
［46］Buriánková K, Doucet-Populaire F, Dorson O, et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother,2004,48(1):143-150.
［47］Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother, 2008,52(2):800-801.

[1]	张静, 陈曦, 王彬, 付雷, 陆宇, 陈效友. 改良单叠氮丙啶-荧光定量PCR法的建立及其检测抗结核药物活性的价值[J]. 中国防痨杂志, 2020, 42(5): 472-480.
[2]	高天慧,舒薇,高静韬,陆宇,李琦. 254例耐药肺结核患者克拉霉素耐药情况及影响因素分析[J]. 中国防痨杂志, 2020, 42(3): 259-265.
[3]	陈浩,武楠楠,胡文辉,杨忠金. 抗结核药物作用新靶点及其研究进展[J]. 中国防痨杂志, 2020, 42(3): 286-292.
[4]	王静,张蒙,贺建清. 抗结核药物引起的艰难梭状芽胞杆菌相关性腹泻一例并文献复习[J]. 中国防痨杂志, 2020, 42(3): 293-296.
[5]	邱磊,张少言,郭晓燕,付际游,田黎明,张惠勇,鹿振辉. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值[J]. 中国防痨杂志, 2020, 42(2): 108-114.
[6]	王雪迪,江锋,代倩兰,王京,王冬梅. 中西医联合与单纯西医治疗结核病所致药物性肝损伤的对比分析(2000—2019年文献复习)[J]. 中国防痨杂志, 2020, 42(2): 126-132.
[7]	李蒙, 路丽苹, 江琦, 洪建军, 高谦, 杨崇广, 郭晓芹. 上海市松江区肺结核患者治疗药品的种类及费用分析[J]. 中国防痨杂志, 2020, 42(12): 1329-1332.
[8]	唐亮, 鲍玉成, 张文龙. 抗结核药品对肠道菌群的改变及其对机体的影响[J]. 中国防痨杂志, 2020, 42(12): 1333-1338.
[9]	陈曦,刘忠泉,王彬,朱慧,付雷,李媛媛,陆宇. 14种抗结核药物在巨噬细胞内的抗结核活性评价[J]. 中国防痨杂志, 2019, 41(9): 993-998.
[10]	《中国防痨杂志》编委会. 耐药结核病化疗过程中药品不良反应处理的专家共识[J]. 中国防痨杂志, 2019, 41(6): 591-603.
[11]	邓国防,张培泽,杨敏,付亮. 二线注射剂治疗耐多药结核病的现状与思考[J]. 中国防痨杂志, 2019, 41(6): 604-608.
[12]	赵皎洁,陆宇. 抗结核药物药代动力学/药效学的研究及进展[J]. 中国防痨杂志, 2019, 41(6): 700-704.
[13]	郭存炳,李辉,郑淑兰. 参芪十一味颗粒治疗抗结核药物所致白细胞减少症的疗效[J]. 中国防痨杂志, 2018, 40(3): 274-279.
[14]	吴虹，李钧，安琴，等. 水飞蓟宾胶囊预防抗结核药物所致肝损伤的疗效分析[J]. 中国防痨杂志, 2017, 39(7): 757-760.
[15]	赵嫄，雷倩，党丽云，等. 抗结核药物血药浓度监测工作的思考和展望[J]. 中国防痨杂志, 2017, 39(11): 1228-1232.